MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE (MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE).

How it works

Osmotic laxative that retains water in the bowel lumen via osmotic gradient, inducing diarrhea to cleanse the colon. Sodium sulfate, potassium sulfate, and magnesium sulfate are poorly absorbed, creating an osmotic effect. Additionally, magnesium may stimulate cholecystokinin release.

What the body does with it

Metabolism	Not metabolized; excreted primarily in feces with minimal systemic absorption. Small absorbed amounts are renally excreted.
Excretion	Primarily renal excretion. Approximately 20% of sulfate is absorbed and excreted in urine; the remainder is eliminated fecally as unabsorbed drug. Potassium is mostly reabsorbed; excess is excreted renally.
Half-life	Not applicable as a systemic half-life; the drug acts locally in the gastrointestinal tract. For absorbed sulfate, elimination half-life is approximately 6-8 hours in patients with normal renal function.
Protein binding	Minimal protein binding (<5%) for sulfate and potassium; sodium is not protein bound.
Volume of Distribution	Not applicable for local action; absorbed sulfate distributes primarily in extracellular fluid with Vd approximately 0.2-0.3 L/kg.
Bioavailability	Sulfate bioavailability is approximately 20% after oral administration; potassium and sodium are highly bioavailable (>90%) but the combination is designed for local effect.
Onset of Action	Oral administration: onset of bowel evacuation within 1-3 hours.
Duration of Action	Duration of bowel cleansing effect is approximately 3-6 hours after administration, with complete evacuation within 12 hours.

Classification & Brands

Dosing & administration

For bowel cleansing prior to colonoscopy: 3 packets (each packet contains 1.6 g magnesium sulfate anhydrous, 3.13 g potassium sulfate, and 1.5 g sodium sulfate) dissolved in water to make 16 ounces, followed by additional water: administer as a split-dose regimen (one 16-ounce solution the evening before and one 16-ounce solution on the day of the procedure).

Dosage form	SOLUTION
Renal impairment	Contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²). For moderate impairment (eGFR 30-59 mL/min/1.73 m²): use with caution, consider reduced volume or alternate agent.
Liver impairment	No specific dose adjustment required for hepatic impairment; use caution in severe hepatic impairment due to potential electrolyte disturbances.
Pediatric use	Safety and efficacy in pediatric patients have not been established; not recommended for children under 12 years.
Geriatric use	Elderly patients may be more susceptible to electrolyte imbalances and volume depletion; ensure adequate hydration and monitor electrolytes before and after use.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE (MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE).

Breastfeeding	Magnesium sulfate is excreted into breast milk; M/P ratio unknown. Peak milk concentration occurs 1-2 hours after maternal dose. Sulfates (potassium, sodium) are minimally transferred. Infant exposure is low; caution advised, avoid breastfeeding for 8 hours after administration.
Teratogenic Risk	Category C: Magnesium sulfate is associated with fetal abnormalities (e.g., hypocalcemia, skeletal demineralization) when used long-term in pregnancy; risks from single-dose bowel preparation are minimal. Potassium sulfate and sodium sulfate are not teratogenic in animal studies at clinically relevant doses. No known human teratogenicity from brief exposure as colonoscopy preparation.

Warnings & precautions

■ FDA Black Box Warning

Risk of serious fluid and electrolyte disturbances, including dehydration, hyponatremia, and renal impairment. Use caution in patients with renal insufficiency, heart failure, or those taking medications affecting fluid/electrolyte balance.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Gastrointestinal obstruction, ileus, perforation","Gastric retention, bowel perforation","Toxic colitis, megacolon","Hypersensitivity to any component","Severe renal impairment (eGFR <30 mL/min)","Hemodynamically unstable patients","Pregnancy (relative, based on risk-benefit)"]

Clinical Precautions

Precautions

["Risk of electrolyte imbalances (hypokalemia, hyponatremia, hypermagnesemia)","Dehydration and volume depletion","Renal impairment (may accumulate magnesium)","Cardiac arrhythmias (with electrolyte abnormalities)","Seizures (hyponatremia risk)","Gastrointestinal distress, nausea, vomiting, bloating","Use caution in patients with impaired gag reflex, aspiration risk, or GI obstruction"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE (MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE).

How it works

What the body does with it

Metabolism	Not metabolized; excreted primarily in feces with minimal systemic absorption. Small absorbed amounts are renally excreted.
Excretion	Primarily renal excretion. Approximately 20% of sulfate is absorbed and excreted in urine; the remainder is eliminated fecally as unabsorbed drug. Potassium is mostly reabsorbed; excess is excreted renally.
Half-life	Not applicable as a systemic half-life; the drug acts locally in the gastrointestinal tract. For absorbed sulfate, elimination half-life is approximately 6-8 hours in patients with normal renal function.
Protein binding	Minimal protein binding (<5%) for sulfate and potassium; sodium is not protein bound.
Volume of Distribution	Not applicable for local action; absorbed sulfate distributes primarily in extracellular fluid with Vd approximately 0.2-0.3 L/kg.
Bioavailability	Sulfate bioavailability is approximately 20% after oral administration; potassium and sodium are highly bioavailable (>90%) but the combination is designed for local effect.
Onset of Action	Oral administration: onset of bowel evacuation within 1-3 hours.
Duration of Action	Duration of bowel cleansing effect is approximately 3-6 hours after administration, with complete evacuation within 12 hours.

Classification & Brands

Dosing & administration

Dosage form	SOLUTION
Renal impairment	Contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²). For moderate impairment (eGFR 30-59 mL/min/1.73 m²): use with caution, consider reduced volume or alternate agent.
Liver impairment	No specific dose adjustment required for hepatic impairment; use caution in severe hepatic impairment due to potential electrolyte disturbances.
Pediatric use	Safety and efficacy in pediatric patients have not been established; not recommended for children under 12 years.
Geriatric use	Elderly patients may be more susceptible to electrolyte imbalances and volume depletion; ensure adequate hydration and monitor electrolytes before and after use.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE (MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE).

Breastfeeding	Magnesium sulfate is excreted into breast milk; M/P ratio unknown. Peak milk concentration occurs 1-2 hours after maternal dose. Sulfates (potassium, sodium) are minimally transferred. Infant exposure is low; caution advised, avoid breastfeeding for 8 hours after administration.
Teratogenic Risk	Category C: Magnesium sulfate is associated with fetal abnormalities (e.g., hypocalcemia, skeletal demineralization) when used long-term in pregnancy; risks from single-dose bowel preparation are minimal. Potassium sulfate and sodium sulfate are not teratogenic in animal studies at clinically relevant doses. No known human teratogenicity from brief exposure as colonoscopy preparation.